EL7.AI
StocksMediumUpdated•Originally published 12 November 2026•Updated 12 November 2026•
1 min read

X-energy and Fennec Pharmaceuticals Report Strong Q3 2026 Revenue Growth

Key Facts

1X-energy reported Q3 revenues and grant income of $66.3 million, up from $30.4 million in the prior year period.
2Fennec Pharmaceuticals reported net product sales of $19.4 million, representing a 56% year-over-year increase.
3X-energy selected Fluor Corporation to advance nuclear engineering and design for its second Xe-100 project.

X-energy reported Q3 2026 revenues and grant income of $66.3 million, up from $30.4 million in the prior year period. According to GlobeNewswire, the company's operating expenses rose 139% to $169.9 million, while its consolidated net loss narrowed to $83.7 million. Separately, Fennec Pharmaceuticals reported net product sales of $19.4 million, representing a 56% year-over-year increase.

XE shares closed at $10.94 on November 11, 2026, as the company maintained total liquidity of $1,805.5 million at the end of September 2026. In the engineering sector, FLR closed at $50.62 on November 11, 2026, following its selection to advance design work for the Xe-100 project. FENC shares closed at $10.64 on the same date, reflecting its continued commercial sales growth.

Open on chart